01/09/2020
Gutenberg doesn't change how WordPress worksby admin / December 8, 2018 779 views
Related Posts
AJ Vaccines To Develop Vaccine for COVID-19
521 views
Danish vaccine manufacturer AJ Vaccines has initiated the development of a new vaccine, effective for protection against coronavirus COVID-19. The vaccine candidate will use technology to raise strong immune responses while being well tolerated and to meet potential global demand in 2021.
“This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the current global challenge of coronavirus COVID-19”, says Dr Tabassum Khan, Chairman to AJ Vaccines.
Committed to prevent serious disease globally
“The impact of the COVID-19 disease globally is developing by the hour and we are committed to a world free of serious diseases across all generations. Our employees are aware of the current challenges and are dedicated to finding solutions to the COVID-19 challenge with state-of-the-art technology”, says Jesper Helmuth Larsen, CEO AJ Vaccines.
High protection, low risk of side effects
“The main principle of vaccination is to proactively induce a protective immune response by mimicking the natural interaction of infectious pathogens with our immune system. Modern antigen technology allows for the production of vaccines combining high protection with a low reactogenicity and favorable safety profile as compared to some of the more traditional vaccines. Our aim is to combine the best possibly designed antigens in such a way to mimic closely the authentic native structures of the virus. Similar technologies were previously successfully applied in US FDA-approved vaccines. In short, the use of such technology is expected to induce the relevant immune responses and therefore protect against disease with a lower risk for side effects”, concludes Jerome Cabannes, COO AJ Vaccines.
Notes for editors
AJ Vaccines Group based in Copenhagen Denmark develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough) and polio. In addition, the Group manufactures Tuberculin for screening and diagnosis of high-risk patients for infection with TB, and BCG Culture (Danish strain 1331) for the standard treatment for intermediate and high-risk non-muscle invasive bladder cancer. Our affiliate office in Malaysia focuses on in-licensing and developing, newer more effective vaccines and diagnostics relevant to the region, such as leptospirosis, influenza and cholera.
The company has some 750 employees and expects to expand its skilled workforce in order to fulfill the ambitious growth plans.
See more at: http://www.ajvaccines.com/
Source : https://www.businesswire.com/news/home/20200306005124/en/AJ-Vaccines-Develop-Vaccine-COVID-19
QliqSOFT Launches COVID-19 Virtual Patient Communication Kit
504 views
Technology solution designed to combat the spread of virus and ensure proper care of those impacted
To help hospitals and health systems meet the potential patient-surge associated with COVID-19 outbreaks across the country, QliqSOFT,Inc. today announced the release of an all-in-one COVID-19 Virtual Patient Communication Kit that provides digital tools for screening and education in line with the Center for Disease Control’s (CDC) guidelines.
Each kit includes:
- AI-driven chatbots for instant engagement
- Video Conferencing to support telemedicine recommended by the CDC
- Secure Mobile Messaging
- Live Care Navigator Escalation
- Dynamic FAQ library including CDC/WHO resources
- Virtual deployment via QR Codes, SMS campaigns, or web/portal hosted widget
- White-labeled to support health system authority through brand awareness
- Mobile solution with no app download required
The kit allows patients to receive in-home advice and avoid emergency departments or clinics unless their condition warrants in-person care.
These secure tools allow patients to review science-sourced education from the CDC and World Health Organization and conduct personal risk assessments much like the clinical decision support programs used widely by clinicians today. Even if patients are asymptomatic and have no known exposure risks they’re better positioned with education and community resources.
“Virtual Communication Kits are the best way to combat the spread of virus while caring for the ones who are already infected,” said Krishna Kurapati, CEO and Founder of QliqSOFT, Inc.
Hospitals interested in QliqSOFT’s COVID-19 Virtual Patient Communication Kit should request more information here. Clinical Support Specialists are on standby to get the solution in place for health systems rapidly.
About QliqSOFT, Inc.
With its unique cloud pass-thru architecture, QliqSOFT’s Secure Texting, On-Call Scheduling, Patient Communication, and Clinical Collaboration solutions are trusted by over 1,000 Hospitals, Home Health, and Hospice Organizations to deliver HIPAA-compliant, reliable, and real-time communication between doctors, nurses, caregivers, and patients. To learn more, visit www.qliqsoft.com.
